PPARA and primary biliary cholangitis: With its antipruritic, anticholestatic, and anti-inflammatory effects in fibrosing cholangiopathies such as PSC or PBC and its safety profile, bezafibrate—and potentially other PPAR agonists—should become the 1st line treatment in cholestasis-associated pruritus in the future.